These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

325 related items for PubMed ID: 21482964

  • 1. Homocysteine-lowering and cardiovascular disease outcomes in kidney transplant recipients: primary results from the Folic Acid for Vascular Outcome Reduction in Transplantation trial.
    Bostom AG, Carpenter MA, Kusek JW, Levey AS, Hunsicker L, Pfeffer MA, Selhub J, Jacques PF, Cole E, Gravens-Mueller L, House AA, Kew C, McKenney JL, Pacheco-Silva A, Pesavento T, Pirsch J, Smith S, Solomon S, Weir M.
    Circulation; 2011 Apr 26; 123(16):1763-70. PubMed ID: 21482964
    [Abstract] [Full Text] [Related]

  • 2. Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
    Jamison RL, Hartigan P, Kaufman JS, Goldfarb DS, Warren SR, Guarino PD, Gaziano JM, Veterans Affairs Site Investigators.
    JAMA; 2007 Sep 12; 298(10):1163-70. PubMed ID: 17848650
    [Abstract] [Full Text] [Related]

  • 3. B-Vitamin Therapy for Kidney Transplant Recipients Lowers Homocysteine and Improves Selective Cognitive Outcomes in the Randomized FAVORIT Ancillary Cognitive Trial.
    Scott TM, Rogers G, Weiner DE, Livingston K, Selhub J, Jacques PF, Rosenberg IH, Troen AM.
    J Prev Alzheimers Dis; 2017 Sep 12; 4(3):174-182. PubMed ID: 29182708
    [Abstract] [Full Text] [Related]

  • 4. Interventions for lowering plasma homocysteine levels in dialysis patients.
    Nigwekar SU, Kang A, Zoungas S, Cass A, Gallagher MP, Kulshrestha S, Navaneethan SD, Perkovic V, Strippoli GF, Jardine MJ.
    Cochrane Database Syst Rev; 2016 May 31; 2016(5):CD004683. PubMed ID: 27243372
    [Abstract] [Full Text] [Related]

  • 5. Aspirin Use and Incident Cardiovascular Disease, Kidney Failure, and Death in Stable Kidney Transplant Recipients: A Post Hoc Analysis of the Folic Acid for Vascular Outcome Reduction in Transplantation (FAVORIT) Trial.
    Dad T, Tighiouart H, Joseph A, Bostom A, Carpenter M, Hunsicker L, Kusek JW, Pfeffer M, Levey AS, Weiner DE.
    Am J Kidney Dis; 2016 Aug 31; 68(2):277-286. PubMed ID: 26947217
    [Abstract] [Full Text] [Related]

  • 6. Interventions for lowering plasma homocysteine levels in kidney transplant recipients.
    Kang A, Nigwekar SU, Perkovic V, Kulshrestha S, Zoungas S, Navaneethan SD, Cass A, Gallagher MP, Ninomiya T, Strippoli GF, Jardine MJ.
    Cochrane Database Syst Rev; 2015 May 04; 2015(5):CD007910. PubMed ID: 25938479
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Homocysteine-lowering vitamin B treatment decreases cardiovascular events in hemodialysis patients.
    Righetti M, Serbelloni P, Milani S, Ferrario G.
    Blood Purif; 2006 May 04; 24(4):379-86. PubMed ID: 16755160
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Lowering homocysteine in patients with ischemic stroke to prevent recurrent stroke, myocardial infarction, and death: the Vitamin Intervention for Stroke Prevention (VISP) randomized controlled trial.
    Toole JF, Malinow MR, Chambless LE, Spence JD, Pettigrew LC, Howard VJ, Sides EG, Wang CH, Stampfer M.
    JAMA; 2004 Feb 04; 291(5):565-75. PubMed ID: 14762035
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of folic acid and B vitamins on risk of cardiovascular events and total mortality among women at high risk for cardiovascular disease: a randomized trial.
    Albert CM, Cook NR, Gaziano JM, Zaharris E, MacFadyen J, Danielson E, Buring JE, Manson JE.
    JAMA; 2008 May 07; 299(17):2027-36. PubMed ID: 18460663
    [Abstract] [Full Text] [Related]

  • 14. Effects of homocysteine-lowering with folic acid plus vitamin B12 vs placebo on mortality and major morbidity in myocardial infarction survivors: a randomized trial.
    Study of the Effectiveness of Additional Reductions in Cholesterol and Homocysteine (SEARCH) Collaborative Group, Armitage JM, Bowman L, Clarke RJ, Wallendszus K, Bulbulia R, Rahimi K, Haynes R, Parish S, Sleight P, Peto R, Collins R.
    JAMA; 2010 Jun 23; 303(24):2486-94. PubMed ID: 20571015
    [Abstract] [Full Text] [Related]

  • 15. Treatment of hyperhomocysteinemia in hemodialysis patients and renal transplant recipients.
    Bostom AG, Shemin D, Gohh RY, Beaulieu AJ, Bagley P, Massy ZA, Jacques PF, Dworkin L, Selhub J.
    Kidney Int Suppl; 2001 Feb 23; 78():S246-52. PubMed ID: 11169020
    [Abstract] [Full Text] [Related]

  • 16. Homocysteine and renal disease.
    van Guldener C, Robinson K.
    Semin Thromb Hemost; 2000 Feb 23; 26(3):313-24. PubMed ID: 11011849
    [Abstract] [Full Text] [Related]

  • 17. Controlled trials of very high dose folic acid, vitamins B12 and B6, intravenous folinic acid and serine for treatment of hyperhomocysteinemia in ESRD.
    Gonin JM, Nguyen H, Gonin R, Sarna A, Michels A, Masri-Imad F, Bommareddy G, Chassaing C, Wainer I, Loya A, Cary D, Barker LF, Assefi A, Greenspan R, Mahoney D, Wilcox CS.
    J Nephrol; 2003 Feb 23; 16(4):522-34. PubMed ID: 14696754
    [Abstract] [Full Text] [Related]

  • 18. Uremic hyperhomocysteinemia: a randomized trial of folate treatment for the prevention of cardiovascular events.
    Vianna AC, Mocelin AJ, Matsuo T, Morais-Filho D, Largura A, Delfino VA, Soares AE, Matni AM.
    Hemodial Int; 2007 Apr 23; 11(2):210-6. PubMed ID: 17403173
    [Abstract] [Full Text] [Related]

  • 19. Vitamin supplements and cardiovascular risk: review of the randomized trials of homocysteine-lowering vitamin supplements.
    Clarke R, Armitage J.
    Semin Thromb Hemost; 2000 Apr 23; 26(3):341-8. PubMed ID: 11011852
    [Abstract] [Full Text] [Related]

  • 20. Homocysteine-lowering therapy and stroke risk, severity, and disability: additional findings from the HOPE 2 trial.
    Saposnik G, Ray JG, Sheridan P, McQueen M, Lonn E, Heart Outcomes Prevention Evaluation 2 Investigators.
    Stroke; 2009 Apr 23; 40(4):1365-72. PubMed ID: 19228852
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.